PRVA241220P35000
- 0.00
- 0.000.00%
Privia Health Newsroom
Privia Health Is Maintained at Overweight by JP Morgan
Privia Health Gr Analyst Ratings
J.P. Morgan Maintains Privia Health(PRVA.US) With Buy Rating, Raises Target Price to $28
Privia Health Group: Strong Performance and Growth Potential Justifies Buy Rating
Stifel Nicolaus Sticks to Its Buy Rating for Privia Health Group (PRVA)
A Quick Look at Today's Ratings for Privia Health(PRVA.US), With a Forecast Between $25 to $29
Privia Health Is Maintained at Equal-Weight by Barclays
Privia Health Gr Analyst Ratings
Truist Securities Maintains Buy on Privia Health Gr, Raises Price Target to $27
A Quick Look at Today's Ratings for Privia Health(PRVA.US), With a Forecast Between $22 to $28
Analysts Offer Insights on Healthcare Companies: Solid Biosciences (SLDB), Privia Health Group (PRVA) and Jazz Pharmaceuticals (JAZZ)
Robust Growth and Strategic Expansion Drive 'Buy' Rating for Privia Health Group
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cross Country Healthcare (CCRN), CVS Health (CVS) and Privia Health Group (PRVA)
Barclays Maintains Privia Health(PRVA.US) With Hold Rating, Maintains Target Price $19
Evercore Maintains Privia Health(PRVA.US) With Buy Rating, Maintains Target Price $22
Privia Health Price Target Announced at $23.00/Share by Keybanc
Privia Health Gr Analyst Ratings
Privia Health Initiated With an Overweight at KeyBanc
Privia Health Initiated With an Overweight at KeyBanc
William Blair Initiates Privia Health(PRVA.US) With Buy Rating